Medical Marijuana and Cannabidiol Research Expansion Act

Bill: 117-hr-8454
Sponsor: Rep. Blumenauer, Earl [D-OR-3]
Introduced: 2022-07-21 in the House
Policy area: Crime and Law Enforcement
Subjects: Alternative treatments
Congressional oversight
Drug safety, medical device, and laboratory regulation
Drug therapy
Drug trafficking and controlled substances
Drug, alcohol, tobacco use
Health personnel
Licensing and registrations
Medical research
Public-private cooperation
Research administration and funding

Summary:
action_date: 2022-07-21
text: 

Medical Marijuana and Cannabidiol Research Expansion Act

 
This bill establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the bill includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes; 
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research; 
 
 allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and 
 
 require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. 


action_date: 2022-07-26
text: 

Medical Marijuana and Cannabidiol Research Expansion Act

 
This bill establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the bill includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes; 
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research; 
 
 allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and 
 
 require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. 


action_date: 2022-11-16
text: 

Medical Marijuana and Cannabidiol Research Expansion Act

 
This bill establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the bill includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes; 
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research; 
 
 allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and 
 
 require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. 


action_date: 2022-12-02
text: 

Medical Marijuana and Cannabidiol Research Expansion Act

 
This act establishes a new, separate registration process to facilitate research on marijuana.
 
Specifically, the act directs the Drug Enforcement Administration (DEA) to follow procedures specified in the act to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
 
The act allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the act directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
 
Finally, the act includes various other provisions, including provisions that
 
 
require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes; 
 
prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research; 
 
 allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and 
 
 require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle. 



Legislative actions:
action_date: 2022-12-02
text: Became Public Law No: 117-215.
action_date: 2022-12-02
text: Became Public Law No: 117-215.
action_date: 2022-12-02
text: Signed by President.
action_date: 2022-12-02
text: Signed by President.
action_date: 2022-11-29
text: Presented to President.
action_date: 2022-11-29
text: Presented to President.
action_date: 2022-11-17
text: Message on Senate action sent to the House.
action_date: 2022-11-16
text: Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
action_date: 2022-11-16
text: Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
action_date: 2022-07-27
text: Received in the Senate, read twice.
action_date: 2022-07-26
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2022-07-26
text: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
action_date: 2022-07-26
text: Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392).(text: CR H7120-7122)
action_date: 2022-07-26
text: Considered as unfinished business. (consideration: CR H7145-7146)
action_date: 2022-07-26
text: At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
action_date: 2022-07-26
text: DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
action_date: 2022-07-26
text: Considered under suspension of the rules. (consideration: CR H7120-7124)
action_date: 2022-07-26
text: Mr. Pallone moved to suspend the rules and pass the bill, as amended.
action_date: 2022-07-21
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2022-07-21
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2022-07-21
text: Introduced in House
action_date: 2022-07-21
text: Introduced in House

Enacted as: number: 117-215